Predictive parameters in patients undergoing percutaneous hepatic perfusion with melphalan for unresectable liver metastases from uveal melanoma: a retrospective pooled analysis

Tong, T.M.L.; Samim, M.; Kapiteijn, E.; Meijer, T.S.; Speetjens, F.M.; Bruning, R.; ... ; Burgmans, M.C. (2022)

Article / Letter to editor

Purpose The aim of this study was to identify positive predictors for survival in uveal melanoma (UM) patients treated with percutaneous hepatic perfusion with melphalan (M-PHP), by retrospectively pooling data from three centers.Materials and Methods Retrospective analysis including patients ( >= 18 years) treated with M-PHP between February 2014 and December 2019 for unresectable liverdominant or liver-only metastases from UM. Predictors for OS were assessed using uni- and multivariate analyses. Other study outcome measures were response rate, progression-free survival (PFS), liver progression-free survival (LPFS), overall survival (OS) and complications according to CTCAEv5.0.Results In total, 101 patients (47.5% males; median age 59.0 years) completed a minimum of one M-PHP. At a median follow-up time of 15.0 months, complete response (CR), partial response (PR), stable disease (SD) and progressive disease were seen in five (5.0%), 55 (54.5%), 30 (29.7%) and 11 (10.9%) patients, respectively, leading to a 89.1% disease control rate. Median PFS, LPFS and OS were 9.0, 11.0 and 20.0 months, respectively. Survival analyses stratified for radiological response demonstrated significant improved survival in patients with CR or PR and SD category. Treatment of the primary tumor with radiotherapy, >= 2 M-PHP and lactate dehydrogenase (LDH) < 248 U/L were correlated with improved OS. Thirty-day mortality was 1.1% (n = 2). Most common complication was hematological toxicity (self-limiting in most cases).Conclusion M-PHP is safe and effective in patients with UM liver metastases. Achieving CR, PR or SD is associated with improved survival. Primary tumor treatment with radiotherapy, normal baseline LDH and > 1 M-PHP cycles are associated with improved OS.

• Uveal melanoma
• Metastases
• Percutaneous hepatic perfusion
• Melphalan

• All authors: Tong, T.M.L.; Samim, M.; Kapiteijn, E.; Meijer, T.S.; Speetjens, F.M.; Bruning, R.; Schroeder, T.H.; El-Sanosy, S.; Maschke, H.; Wacker, F.K.; Vogel, A.; Dewald, C.L.A.; Goeman, J.J.; Burgmans, M.C.
• Date: 2022-08-03
• Journal: CardioVascular and Interventional Radiology
• Volume: 45
• Issue: 9
• Pages: 1304 - 1313
• DOI: doi:10.1007/s00270-022-03225-9
• Link: https://link.springer.com/article/10.1007/s00270-022-03225-9